

Farrokh Dehdashti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5276615/publications.pdf>

Version: 2024-02-01

139
papers

11,141
citations

26626

56
h-index

29154

104
g-index

142
all docs

142
docs citations

142
times ranked

9028
citing authors

#	ARTICLE	IF	CITATIONS
1	A Projection-Domain Low-Count Quantitative SPECT Method for ^{67}Ga -Particle-Emitting Radiopharmaceutical Therapy. IEEE Transactions on Radiation and Plasma Medical Sciences, 2023, 7, 62-74.	3.7	4
2	Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 550-562.	6.4	48
3	^{18}F -FDG PET in Myocardial Viability Assessment: A Practical and Time-Efficient Protocol. Journal of Nuclear Medicine, 2022, 63, 602-608.	5.0	2
4	Coronary circulatory function with increasing obesity: A complex U-shaped curve. European Journal of Clinical Investigation, 2022, 52, e13755.	3.4	10
5	^{18}F -FDG PET/CT Staging of Head and Neck Cancer: Interobserver Agreement and Accuracy—Results from Multicenter ACRIN 6685 Clinical Trial. Journal of Nuclear Medicine, 2022, 63, 1887-1890.	5.0	1
6	An Exploratory Study of Neoadjuvant Cetuximab Followed by Cetuximab and Chemoradiotherapy in Women With Newly Diagnosed Locally Advanced Cervical Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2022, 45, 286-293.	1.3	0
7	Pilot Study: PARP1 Imaging in Advanced Prostate Cancer. Molecular Imaging and Biology, 2022, 24, 853-861.	2.6	3
8	Durable remission after rechallenge with ipilimumab and nivolumab in metastatic Merkel cell carcinoma refractory to avelumab: Any role for sequential immunotherapy?. Journal of Dermatology, 2021, 48, e80-e81.	1.2	10
9	CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma. ACS Nano, 2021, 15, 1186-1198.	14.6	32
10	Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy. Nature Communications, 2021, 12, 733.	12.8	33
11	Standardized Uptake Value for ^{18}F -Fluorodeoxyglucose Is a Marker of Inflammatory State and Immune Infiltrate in Cervical Cancer. Clinical Cancer Research, 2021, 27, 4245-4255.	7.0	15
12	Detection of additional primary neoplasms on ^{18}F -Fluciclovine PET/CT in patients with primary prostate cancer. Journal of Nuclear Medicine, 2021, , jnumed.121.262647.	5.0	3
13	PET Imaging for Gynecologic Malignancies. Radiologic Clinics of North America, 2021, 59, 813-833.	1.8	6
14	Practical considerations for quantitative clinical SPECT/CT imaging of alpha particle emitting radioisotopes. Theranostics, 2021, 11, 9721-9737.	10.0	12
15	Phase II study of dacarbazine given with modern prophylactic anti-emetics and growth factor support to patients with metastatic, resistant soft tissue, and bone sarcoma. Rare Tumors, 2021, 13, 203636132110524.	0.6	1
16	Radiologic Assessment of Groin Lymph Nodes in Pelvic Malignancies. International Journal of Gynecological Cancer, 2020, 30, 947-953.	2.5	4
17	Induced Remission of Metastatic Squamous Cell Carcinoma with an Immune Checkpoint Inhibitor in a Patient with Recessive Dystrophic Epidermolysis Bullosa. Case Reports in Oncology, 2020, 13, 911-915.	0.7	14
18	FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival. Gynecologic Oncology, 2020, 157, 639-643.	1.4	57

#	ARTICLE	IF	CITATIONS
19	Repeatability of Quantitative Brown Adipose Tissue Imaging Metrics on Positron Emission Tomography with 18F-Fluorodeoxyglucose in Humans. <i>Cell Metabolism</i> , 2019, 30, 212-224.e4.	16.2	21
20	Intensity Modulated Radiation Therapy and Image-Guided Adapted Brachytherapy for Cervix Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 1088-1097.	0.8	57
21	Molecular Imaging for Radiotherapy Planning and Response Assessment for Cervical Cancer. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 493-500.	4.6	15
22	A Role of PET Agents Beyond FDG in Gynecology. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 501-511.	4.6	6
23	Assessment of Copper Nanoclusters for Accurate in Vivo Tumor Imaging and Potential for Translation. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 19669-19678.	8.0	37
24	Measurement Repeatability of ¹⁸ F-FDG PET/CT Versus ¹⁸ F-FDG PET/MRI in Solid Tumors of the Pelvis. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1080-1086.	5.0	23
25	Impact of tumor histology on detection of pelvic and para-aortic nodal metastasis with ¹⁸ F-fluorodeoxyglucose-positron emission tomography in stage IB cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1351-1354.	2.5	8
26	Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 523-530.	2.5	59
27	Preclinical Development of CD38-Targeted [⁸⁹ Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma. <i>Journal of Nuclear Medicine</i> , 2018, 59, 216-222.	5.0	50
28	Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer. <i>British Journal of Cancer</i> , 2018, 118, 72-78.	6.4	46
29	Percutaneous Minimally Invasive Thermal Ablation of Musculoskeletal Lesions. <i>PET Clinics</i> , 2018, 13, 579-585.	3.0	4
30	Spatial relationship of 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography and magnetic resonance diffusion imaging metrics in cervical cancer. <i>EJNMMI Research</i> , 2018, 8, 52.	2.5	11
31	Pretreatment metabolic tumor volume as a prognostic factor in HPV-associated oropharyngeal cancer in the context of AJCC 8th edition staging. <i>Head and Neck</i> , 2018, 40, 2280-2287.	2.0	14
32	Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study. <i>Lancet Oncology</i> , 2018, 19, 1082-1093.	10.7	21
33	Extensive Metastatic Sarcomatoid Renal Cell Carcinoma Evaluated by 18F-FDG PET/CT: a Case Report and Review of Literature. <i>Journal of Kidney Cancer and VHL</i> , 2018, 5, 1-6.	1.0	7
34	Utility of PET/CT to Evaluate Retroperitoneal Lymph Node Metastasis in High-Risk Endometrial Cancer: Results of ACRIN 6671/GOG 0233 Trial. <i>Radiology</i> , 2017, 283, 450-459.	7.3	51
35	Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial. <i>Clinical Cancer Research</i> , 2017, 23, 2186-2194.	7.0	37
36	Association of post-treatment positron emission tomography with locoregional control and survival after radiation therapy for squamous cell carcinoma of the vulva. <i>Radiotherapy and Oncology</i> , 2017, 122, 445-451.	0.6	12

#	ARTICLE	IF	CITATIONS
37	Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma. Head and Neck Pathology, 2017, 11, 338-345.	2.6	9
38	First-in-Man Evaluation of ¹²⁴ I-PCN650: A PET Tracer for Detecting Phosphatidylserine as a Biomarker of the Solid Tumor Microenvironment. Molecular Imaging, 2017, 16, 153601211773334.	1.4	12
39	Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent. Oncotarget, 2017, 8, 104303-104314.	1.8	12
40	Clinical application of PET/MRI in oncology. Journal of Magnetic Resonance Imaging, 2016, 44, 265-276.	3.4	45
41	Indeterminate Findings on Oncologic PET/CT: What Difference Does PET/MRI Make?. Nuclear Medicine and Molecular Imaging, 2016, 50, 292-299.	1.0	9
42	Gold Nanoclusters Doped with ⁶⁴ Cu for CXCR4 Positron Emission Tomography Imaging of Breast Cancer and Metastasis. ACS Nano, 2016, 10, 5959-5970.	14.6	71
43	Radioimmunotherapy-based conditioning for hematopoietic stem cell transplantation: Another step forward. Blood Reviews, 2016, 30, 389-399.	5.7	9
44	Phase 1 Evaluation of [64Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors. Molecular Imaging and Biology, 2016, 18, 446-453.	2.6	40
45	Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial. Gynecologic Oncology, 2016, 142, 413-419.	1.4	65
46	The Emerging Role of PET/MR Imaging in Gynecologic Cancers. PET Clinics, 2016, 11, 425-440.	3.0	18
47	Clinical application of PET/MRI in oncology. Journal of Magnetic Resonance Imaging, 2016, 44, spcone-spcone.	3.4	0
48	[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer. Molecular Imaging and Biology, 2016, 18, 952-959.	2.6	103
49	Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer. Journal of Nuclear Medicine, 2016, 57, 75S-80S.	5.0	43
50	Imaging of Plasma Cell Dyscrasias with FDG-PET/MRI: A Single-Center Experience. Blood, 2016, 128, 5611-5611.	1.4	1
51	PET/MRI Evaluation of Gynecologic Malignancies and Prostate Cancer. Seminars in Nuclear Medicine, 2015, 45, 293-303.	4.6	32
52	[18 F]FHBG PET/CT Imaging of CD34-TK75 Transduced Donor T Cells in Relapsed Allogeneic Stem Cell Transplant Patients: Safety and Feasibility. Molecular Therapy, 2015, 23, 1110-1122.	8.2	18
53	Evaluation of Hypoxia With Copper-Labeled Diacetyl-bis(N-Methylthiosemicarbazone). Seminars in Nuclear Medicine, 2015, 45, 177-185.	4.6	34
54	PET/MRI for the body imager: abdominal and pelvic oncologic applications. Abdominal Imaging, 2015, 40, 1387-1404.	2.0	23

#	ARTICLE	IF	CITATIONS
55	Longitudinal Noninvasive Imaging of Progesterone Receptor as a Predictive Biomarker of Tumor Responsiveness to Estrogen Deprivation Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 1063-1070.	7.0	31
56	Evaluation of Gynecologic Cancer with MR Imaging, ¹⁸ F-FDG PET/CT, and PET/MR Imaging. <i>Journal of Nuclear Medicine</i> , 2015, 56, 436-443.	5.0	90
57	Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in high risk endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5524-5524.	1.6	1
58	Utility of PET-CT vs CT alone to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5585-5585.	1.6	0
59	Suicide genes: monitoring cells in patients with a safety switch. <i>Frontiers in Pharmacology</i> , 2014, 5, 241.	3.5	10
60	A prospective trial comparing FDG \pm PET / CT and CT to assess tumor response to cetuximab in patients with incurable squamous cell carcinoma of the head and neck. <i>Cancer Medicine</i> , 2014, 3, 1493-1501.	2.8	13
61	Diffusion-weighted MRI for staging and evaluation of response in diffuse large B-cell lymphoma: a pilot study. <i>NMR in Biomedicine</i> , 2014, 27, 681-691.	2.8	26
62	A phase I study of the AKT inhibitor MK-2206 plus hormonal therapy in postmenopausal women with estrogen receptor positive (ER+) metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 553-553.	1.6	0
63	Prognostic value of 18F-FDG PET metabolic parameters in oropharyngeal squamous cell carcinoma. <i>Journal of Radiation Oncology</i> , 2013, 2, 27-34.	0.7	30
64	Response to the Letter to the Editor Regarding the Manuscript Entitled "Positron Emission Tomography with [18F]-3-Deoxy-3-Fluorothymidine (FLT) as a Predictor of Outcome in Patients with Locally Advanced Resectable Rectal Cancer: A Pilot Study". <i>Molecular Imaging and Biology</i> , 2013, 15, 786-787.	2.6	0
65	Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. <i>Gynecologic Oncology</i> , 2013, 130, 64-68.	1.4	73
66	A phase 2 trial of induction \pm paclitaxel and cetuximab given with cisplatin and 5-Fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2013, 119, 766-773.	4.1	31
67	Positron Emission Tomography with [18F]-3-Deoxy-3-Fluorothymidine (FLT) as a Predictor of Outcome in Patients with Locally Advanced Resectable Rectal Cancer: a Pilot Study. <i>Molecular Imaging and Biology</i> , 2013, 15, 106-113.	2.6	22
68	Tumor volume and subvolume concordance between FDG \pm PET/CT and diffusion-weighted MRI for squamous cell carcinoma of the cervix. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 37, 431-434.	3.4	44
69	Novel Methods and Tracers for Breast Cancer Imaging. <i>Seminars in Nuclear Medicine</i> , 2013, 43, 324-329.	4.6	52
70	11C-Acetate PET/CT Before Radical Prostatectomy: Nodal Staging and Treatment Failure Prediction. <i>Journal of Nuclear Medicine</i> , 2013, 54, 699-706.	5.0	81
71	Assessment of Cellular Proliferation in Tumors by PET Using ¹⁸ F-ISO-1. <i>Journal of Nuclear Medicine</i> , 2013, 54, 350-357.	5.0	76
72	Assessment of Progesterone Receptors in Breast Carcinoma by PET with 21- ¹⁸ F-Fluoro-16 β ,17 β -(1 β -furylmethylidene)Dioxy]-19-Norpregn-4-Ene-3,20-Dione. <i>Journal of Nuclear Medicine</i> , 2012, 53, 363-370.	5.0	71

#	ARTICLE	IF	CITATIONS
73	Combined PET/CT image characteristics for radiotherapy tumor response in lung cancer. Radiotherapy and Oncology, 2012, 102, 239-245.	0.6	183
74	FDG-PET-based prognostic nomograms for locally advanced cervical cancer. Gynecologic Oncology, 2012, 127, 136-140.	1.4	96
75	The role of positron emission tomography for non-small cell lung cancer. Practical Radiation Oncology, 2011, 1, 282-288.	2.1	6
76	Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1646-1652.	2.0	92
77	18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation. Journal of Nuclear Medicine, 2011, 52, 386-392.	5.0	151
78	Exclusion of Malignancy in Thyroid Nodules with Indeterminate Fine-Needle Aspiration Cytology After Negative ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography: Interim Analysis. World Journal of Surgery, 2010, 34, 1247-1253.	1.6	52
79	Pelvic lymph node ¹⁸ F-fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer. Cancer, 2010, 116, 1469-1475.	4.1	103
80	Lymph Node Staging by Positron Emission Tomography in Cervical Cancer: Relationship to Prognosis. Journal of Clinical Oncology, 2010, 28, 2108-2113.	1.6	262
81	Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis. Radiotherapy and Oncology, 2010, 95, 288-291.	0.6	53
82	Prospective Study of [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Staging of Muscle-Invasive Bladder Carcinoma. Journal of Clinical Oncology, 2009, 27, 4314-4320.	1.6	219
83	Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor-Positive, Aromatase Inhibitor-Resistant Advanced Breast Cancer. JAMA - Journal of the American Medical Association, 2009, 302, 774.	7.4	252
84	Imaging Tumor Phenotype: 1 Plus 1 Is More Than 2. Journal of Nuclear Medicine, 2009, 50, 1567-1569.	5.0	11
85	Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecologic Oncology, 2009, 112, 104-109.	1.4	84
86	Cervical cancer histology and tumor differentiation affect ¹⁸ F-fluorodeoxyglucose uptake. Cancer, 2009, 115, 3548-3554.	4.1	71
87	PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Research and Treatment, 2009, 113, 509-517.	2.5	189
88	PET Radiotracers for Imaging the Proliferative Status of Solid Tumors. PET Clinics, 2009, 4, 1-15.	3.0	23
89	Surveillance FDG-PET Detection of Asymptomatic Recurrences in Patients. Obstetrical and Gynecological Survey, 2009, 64, 457-458.	0.4	0
90	Tumor Hypoxia Detected by Positron Emission Tomography with ⁶⁰ Cu-ATSM as a Predictor of Response and Survival in Patients Undergoing Neoadjuvant Chemoradiotherapy for Rectal Carcinoma: A Pilot Study. Diseases of the Colon and Rectum, 2008, 51, 1641-1648.	1.3	151

#	ARTICLE	IF	CITATIONS
91	Unique site- and time-specific patterns of recurrence following resection of colorectal carcinoma hepatic metastases in patients staged by FDG-PET. Journal of Hepato-Biliary-Pancreatic Surgery, 2008, 15, 483-487.	2.0	6
92	Combined [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography (FDG-PET/CT) for Detection of Recurrent, 131I-Negative Thyroid Cancer. Annals of Surgical Oncology, 2008, 15, 286-292.	1.5	52
93	An Imaging Comparison of ⁶⁴ Cu-ATSM and ⁶⁰ Cu-ATSM in Cancer of the Uterine Cervix. Journal of Nuclear Medicine, 2008, 49, 1177-1182.	5.0	178
94	Assessing Tumor Hypoxia in Cervical Cancer by PET with ⁶⁰ Cu-Labeled Diacetyl-Bis(<i>N</i> - ⁴ -Methylthiosemicarbazone). Journal of Nuclear Medicine, 2008, 49, 201-205.	5.0	221
95	Prognostic Value of Preoperative Positron Emission Tomography in Resected Stage I Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 130-134.	1.1	104
96	Poor Predictive Value of FDG-PET/CT Performed after 2 Cycles of R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLCL). Blood, 2008, 112, 371-371.	1.4	13
97	Association of Posttherapy Positron Emission Tomography With Tumor Response and Survival in Cervical Carcinoma. JAMA - Journal of the American Medical Association, 2007, 298, 2289.	7.4	260
98	The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer, 2007, 110, 1738-1744.	4.1	271
99	Comparison of Molecular Markers of Hypoxia and Imaging with ⁶⁰ Cu-ATSM in Cancer of the Uterine Cervix. Molecular Imaging and Biology, 2007, 9, 278-283.	2.6	88
100	A2-05: Prognostic value of positron emission tomography in resected stage I non-small cell lung cancer. Journal of Thoracic Oncology, 2007, 2, S314.	1.1	0
101	F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecologic Oncology, 2006, 101, 147-151.	1.4	122
102	18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate?. Journal of Nuclear Medicine, 2006, 47, 1808-12.	5.0	183
103	FDG-PET evaluation of vaginal carcinoma. International Journal of Radiation Oncology Biology Physics, 2005, 62, 733-737.	0.8	103
104	Correlation of Severity of FDG-PET Hypometabolism and Interictal Regional Delta Slowing in Temporal Lobe Epilepsy. Epilepsia, 2005, 46, 573-576.	5.1	38
105	Clinical-pathologic conference in general thoracic surgery: Cardiac lymphoma. Journal of Thoracic and Cardiovascular Surgery, 2005, 130, 870-874.	0.8	3
106	Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. Cancer, 2005, 104, 2484-2491.	4.1	168
107	Positron tomographic assessment of androgen receptors in prostatic carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 344-350.	6.4	216
108	FDG uptake in colonic villous adenomas. Annals of Nuclear Medicine, 2005, 19, 331-334.	2.2	25

#	ARTICLE	IF	CITATIONS
109	Positron Emission Tomography in Limited-Stage Small-Cell Lung Cancer: A Prospective Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 3248-3254.	1.6	250
110	Posttherapy [18F] Fluorodeoxyglucose Positron Emission Tomography in Carcinoma of the Cervix: Response and Outcome. <i>Journal of Clinical Oncology</i> , 2004, 22, 2167-2171.	1.6	228
111	Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. <i>Gynecologic Oncology</i> , 2004, 95, 546-551.	1.4	158
112	Neoplasms of the esophagus and stomach. <i>Seminars in Nuclear Medicine</i> , 2004, 34, 198-208.	4.6	52
113	Five-Year Survival After Resection of Hepatic Metastases From Colorectal Cancer in Patients Screened by Positron Emission Tomography With F-18 Fluorodeoxyglucose (FDG-PET). <i>Annals of Surgery</i> , 2004, 240, 438-450.	4.2	541
114	Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix. <i>Gynecologic Oncology</i> , 2003, 90, 572-576.	1.4	94
115	Posttherapy surveillance monitoring of cervical cancer by FDG-PET. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 907-913.	0.8	102
116	Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: Relationship to therapeutic response—a preliminary report. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 1233-1238.	0.8	324
117	Detection of Primary Hepatic Malignancy in Liver Transplant Candidates: Prospective Comparison of CT, MR Imaging, US, and PET. <i>Radiology</i> , 2003, 226, 533-542.	7.3	200
118	Improved prognostic value of 18F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer. <i>Journal of Nuclear Medicine</i> , 2003, 44, 192-7.	5.0	55
119	11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. <i>Journal of Nuclear Medicine</i> , 2003, 44, 549-55.	5.0	209
120	Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. <i>Journal of Nuclear Medicine</i> , 2003, 44, 700-7.	5.0	105
121	Usefulness of Intraoperative Sonography for Revealing Hepatic Metastases from Colorectal Cancer in Patients Selected for Surgery After Undergoing FDG PET. <i>American Journal of Roentgenology</i> , 2002, 178, 353-358.	2.2	60
122	Evaluation of breast and gynecologic cancers by positron emission tomography. <i>Seminars in Roentgenology</i> , 2002, 37, 151-168.	0.6	9
123	Prospective Evaluation of Positron Emission Tomography for the Detection of Groin Node Metastases from Vulvar Cancer. <i>Gynecologic Oncology</i> , 2002, 85, 179-184.	1.4	162
124	Lymph Node Staging by Positron Emission Tomography in Patients With Carcinoma of the Cervix. <i>Journal of Clinical Oncology</i> , 2001, 19, 3745-3749.	1.6	439
125	Metabolic Flare: Indicator of Hormone Responsiveness in Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 2797-2803.	1.6	377
126	Survival of Patients Evaluated by FDG-PET Before Hepatic Resection for Metastatic Colorectal Carcinoma: A Prospective Database Study. <i>Annals of Surgery</i> , 2001, 233, 293-299.	4.2	171

#	ARTICLE	IF	CITATIONS
127	Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Diseases of the Colon and Rectum, 2000, 43, 759-767.	1.3	254
128	FDG PET Evaluation of Mucinous Neoplasms. American Journal of Roentgenology, 2000, 174, 1005-1008.	2.2	300
129	Characterizing Tumors Using Metabolic Imaging: PET Imaging of Cellular Proliferation and Steroid Receptors. Neoplasia, 2000, 2, 71-88.	5.3	81
130	Comparative breast tumor imaging and comparative in vitro metabolism of ^{16}F -[18F]Fluoroestradiol- ^{17}F and ^{16}F -[18f]fluoromoxestrol in isolated hepatocytes. Nuclear Medicine and Biology, 1999, 26, 123-130.	0.6	47
131	FDG-PET Evaluation of Carcinoma of the Cervix. Molecular Imaging and Biology, 1999, 2, 105-109.	0.3	63
132	PET in breast cancer. Seminars in Nuclear Medicine, 1998, 28, 290-302.	4.6	92
133	Utility of FDG-PET for Investigating Unexplained Plasma CEA Elevation in Patients With Colorectal Cancer. Annals of Surgery, 1998, 227, 319-323.	4.2	226
134	Improvement in Staging of Esophageal Cancer With the Addition of Positron Emission Tomography. Annals of Thoracic Surgery, 1997, 64, 770-777.	1.3	234
135	Detection of recurrent and metastatic colorectal cancer: Comparison of positron emission tomography and computed tomography. Annals of Surgical Oncology, 1997, 4, 613-620.	1.5	248
136	FDG-PET Evaluation of Indeterminate Pancreatic Masses. Journal of Computer Assisted Tomography, 1996, 20, 363-369.	0.9	78
137	False-Negative Radionuclide Cisternography in Massive Communicating Hydrocephalus: Value of the Vertex View and CT Correlation. Clinical Nuclear Medicine, 1989, 14, 819-822.	1.3	1
138	Scintigraphic Demonstration of a Large Communicating Posterior Fossa Cyst. Clinical Nuclear Medicine, 1989, 14, 627-628.	1.3	0
139	Diffuse Muscle Uptake of Technetium-99M MDP in a Patient with Lung Cancer. Clinical Nuclear Medicine, 1988, 13, 538-540.	1.3	2